Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen

Sebastian Ochsenreither, Ravindra Majeti, Thomas Schmitt, Derek Stirewalt, Ulrich Keilholz, Keith R. Loeb, Brent Wood, Yongiae E. Choi, Marie Bleakley, Edus H. Warren, Michael Hudecek, Yoshiki Akatsuka, Irving L. Weissman, Philip D. Greenberg

Blood (2012) 119 (23): 5492–5501.

https://doi.org/10.1182/blood-2011-07-365890

Published: 2012

Includes: Supplemental data

Journal Articles

Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts

Olga Blau, Claudia Dorothea Baldus, Wolf-Karsten Hofmann, Gundula Thiel, Florian Nolte, Thomas Burmeister, Seval Türkmen, Ouidad Benlasfer, Elke Schümann, Annette Sindram, Mara Molkentin, Stefan Mundlos, Ulrich Keilholz, Eckhard Thiel, Igor Wolfgang Blau

Blood (2011) 118 (20): 5583–5592.

https://doi.org/10.1182/blood-2011-03-343467

Published: 2011

Journal Articles

A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS

Ulrich Keilholz, Anne Letsch, Antonia Busse, Anne Marie Asemissen, Sandra Bauer, Igor Wolfgang Blau, Wolf-Karsten Hofmann, Lutz Uharek, Eckhard Thiel, Carmen Scheibenbogen

Blood (2009) 113 (26): 6541–6548.

https://doi.org/10.1182/blood-2009-02-202598

Published: 2009

Journal Articles

Analysis of Immunological and Clinical Response Kinetics to WT1 Peptide Vaccine in Patients with AML and MDS: Need for Supplementation of IWG Response Criteria?.

Ulrich Keilholz, MD, Anne Letsch, MD, Antonia Busse, MD, Annemarie Asemissen, MD, Igor W. Blau, MD, Wolf K. Hofmann, MD, Lutz Uharek, MD, Eckhard Thiel, MD, Carmen Scheibenbogen, MD

Blood (2007) 110 (11): 902.

https://doi.org/10.1182/blood.V110.11.902.902

Published: 2007

Journal Articles

Clinical and Immunological Activity of WT1 Peptide Vaccination in Patients with Acute Myeloid Leukemia and Myelodysplasia: Results of a Phase II Trial.

Ulrich Keilholz, MD, Anne Letsch, Antonia Busse, Anne M. Asemissen, Alexander Schmittel, Wolf K. Hofmann, Lutz Uharek, Igor W. Blau, Eckhard Thiel, Carmen Scheibenbogen

Blood (2006) 108 (11): 567.

https://doi.org/10.1182/blood.V108.11.567.567

Published: 2006

Journal Articles

Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2

Robert Godal, Ulrich Keilholz, Lutz Uharek, Anne Letsch, Anne Marie Asemissen, Antonia Busse, Il-Kang Na, Eckhard Thiel, Carmen Scheibenbogen

Blood (2006) 107 (8): 3205–3211.

https://doi.org/10.1182/blood-2005-07-2880

Published: 2006

Journal Articles

Quantitative Analysis of Wilms’ Tumor Gene 1(WT1) Expression in Acute Lymphoblastic Leukemia (ALL) of Adults Reveals Lower WT1 Levels Than in Acute Myeloid Leukemias (AML) and Varying Expression Levels between Individual Patients among Different ALL Subgroups.

Jan M. Siehl, MD, Eckhard Thiel, MD, Dieter Hoelzer, MD, Stefan Schwartz, MD, Ulrich Keilholz, MD

Blood (2005) 106 (11): 4545.

https://doi.org/10.1182/blood.V106.11.4545.4545

Published: 2005

Journal Articles

Expression of the chemokine receptors CXCR4, CXCR5, and CCR7 in primary central nervous system lymphoma

Kristoph Jahnke, Sarah E. Coupland, Il-Kang Na, Christoph Loddenkemper, Ulrich Keilholz, Agnieszka Korfel, Harald Stein, Eckhard Thiel, Carmen Scheibenbogen

Blood (2005) 106 (1): 384–385.

https://doi.org/10.1182/blood-2005-01-0324

Published: 2005

Journal Articles

A monoclonal melanoma-specific T-cell population phenotypically indistinguishable from CD3 + LGL-leukemia

Danila Valmori, Maha Ayyoub, Charles S. Hesdorffer, Ulrich Keilholz, Carmen Scheibenbogen

Blood (2003) 101 (11): 4643–4644.

https://doi.org/10.1182/blood-2003-03-0828

Published: 2003

Journal Articles

CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia

Carmen Scheibenbogen, Anne Letsch, Eckhard Thiel, Alexander Schmittel, Volker Mailaender, Steffi Baerwolf, Dirk Nagorsen, Ulrich Keilholz

Blood (2002) 100 (6): 2132–2137.

https://doi.org/10.1182/blood-2002-01-0163

Published: 2002

NARROW

Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen

Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts

A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS

Analysis of Immunological and Clinical Response Kinetics to WT1 Peptide Vaccine in Patients with AML and MDS: Need for Supplementation of IWG Response Criteria?.

Clinical and Immunological Activity of WT1 Peptide Vaccination in Patients with Acute Myeloid Leukemia and Myelodysplasia: Results of a Phase II Trial.

Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2

Quantitative Analysis of Wilms’ Tumor Gene 1(WT1) Expression in Acute Lymphoblastic Leukemia (ALL) of Adults Reveals Lower WT1 Levels Than in Acute Myeloid Leukemias (AML) and Varying Expression Levels between Individual Patients among Different ALL Subgroups.

Expression of the chemokine receptors CXCR4, CXCR5, and CCR7 in primary central nervous system lymphoma

A monoclonal melanoma-specific T-cell population phenotypically indistinguishable from CD3 + LGL-leukemia

CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only